The U.S. Food and Drug Administration is once again in a state of transition. Dr. Marty Makary, who served as FDA Commissioner for just over one year, resigned on Tuesday. This ends weeks of speculation about whether he would be fired by the White House. Deputy Commissioner for Food Kyle Diamantas has been named acting commissioner as the search for a permanent leader begins.

For everyday Americans, this leadership change at one of the nation’s most important health agencies raises real questions. The FDA oversees the safety of the food we eat, the prescription drugs we take, the vaccines that protect us, and the medical devices doctors use. When the top job changes hands, it can affect how quickly new treatments reach patients and how strictly safety rules are enforced.

Why Did Makary Leave?

The resignation was first reported by Politico. According to administration officials, the decision came directly from Health and Human Services Secretary Robert F. Kennedy Jr. The Wall Street Journal had reported the previous week that President Trump had approved a plan to remove Makary from his position.

“It was really Secretary Kennedy himself who made this decision,” an unnamed administration official told Politico. While the White House had to sign off on the plan, the final call belonged to Kennedy.

Makary’s departure marks the second major health agency chief to leave under the current administration. Last August, CDC Director Susan Monarez was also fired. This pattern of turnover at the top of federal health agencies is unusual and has drawn concern from public health experts.

A Turbulent 13 Months at the FDA

Makary’s time as commissioner was anything but quiet. His 13 months in charge were filled with turmoil, including mass layoffs and constant changes among top agency officials. One of the most notable examples involved Dr. Vinay Prasad, who was fired from his role as director of the FDA’s Center for Biologics Evaluation and Research, then re-hired, and then left the agency for a second time last month.

The agency’s top drug regulator position has been a revolving door. Under Makary, the role was held by a series of short-term leaders:

• George Tidmarsh, MD, PhD
• Richard Pazdur, MD
• Jacqueline Corrigan-Curay, MD
• Currently, Tracy Beth Hoeg, MD, PhD, serves as acting director

This kind of instability at the top can slow down decision-making. When leaders leave, projects stall. New leaders often want to review ongoing work. For drug companies waiting for approval on new treatments, these delays can mean years of waiting. For patients, it can mean slower access to potentially life-saving medications.

Pressures From All Sides

Makary faced intense pressure from multiple groups at once. Pharmaceutical companies grew frustrated with what they described as inconsistent reviews of their products. When a company spends millions developing a new drug, unpredictable FDA reviews create financial risk and uncertainty.

At the same time, Kennedy pushed Makary to scrutinize the safety of vaccines, drugs, and food additives more closely. Republicans wanted the agency to restrict access to the abortion pill mifepristone, sold under the brand name Mifeprex. Some Republicans accused Makary of slow-walking a review of that medication.

On top of all this, President Trump wanted Makary to authorize flavored vapes and other nicotine products. Makary finally did approve those products earlier this month, just before his resignation.

Health policy experts say this level of cross-pressure is unhealthy for an agency that should base its decisions on science, not politics. “The FDA’s credibility depends on its independence,” said one former agency official who spoke on condition of anonymity. “When commissioners are pulled in multiple political directions, public trust suffers.”

Controversial Changes Under Makary

During his short tenure, Makary pushed through a number of significant and controversial changes to how the FDA operates. These included:

• Creating the Commissioner’s National Priority Voucher, a program that gives companies special incentives for developing certain drugs
• Cutting the number of required studies for drug approval from two to one, which critics say could weaken safety evidence
• Incorporating Bayesian statistical methods into clinical trials, a technical change in how data is analyzed

Perhaps the most controversial changes involved COVID-19 vaccines. Makary and Prasad developed a new approach that allowed immunogenicity endpoints for high-risk groups. In plain language, this means they approved a different standard for proving vaccines work in people at highest risk of severe COVID. For lower-risk groups, they called for randomized controlled trials, which are the gold standard of medical research but take much longer to complete.

They also rolled back wider approval for COVID shots, adding limitations for certain groups. This meant fewer people were officially recommended to receive updated COVID vaccines.

In what may have been the most shocking moment of Makary’s tenure, Prasad claimed in an internal memo that the agency had linked COVID shots to the deaths of 10 children. He made this claim without providing any evidence. The statement caused widespread confusion and alarm among parents and public health officials.

Experts note that multiple large studies have found no link between COVID vaccines and death in children. The CDC and independent researchers continue to monitor vaccine safety closely.

What Happens Next?

It is not clear what will happen to all of the initiatives Makary started. Many of the programs he introduced never went through the formal federal rulemaking process. This means they could be easily overturned by the next commissioner.

Kyle Diamantas, the acting commissioner, appears to be the top internal candidate to run the agency permanently. However, other names are being discussed. According to Axios, potential candidates include:

• Brett Giroir, MD, who served as U.S. assistant secretary for health during the first Trump administration
• Stephen Hahn, MD, who was FDA Commissioner during the first Trump administration

Both men have experience leading during public health emergencies. Giroir oversaw COVID testing efforts. Hahn led the FDA through the early stages of the pandemic and the initial vaccine rollout.

What This Means for You

When the FDA has leadership instability, the effects eventually reach patients and consumers. Here are some practical things to keep in mind:

• Drug approvals may slow down. Until a permanent commissioner is confirmed, major decisions on new drugs could be delayed. This primarily affects people waiting for new treatments for serious conditions.
• Food safety oversight could change. The acting commissioner comes from the food division, which may signal a shift in priorities. Food recalls and safety inspections could be affected.
• Vaccine policy remains uncertain. The changes Makary made to COVID vaccine approvals could be reversed, which might affect who is recommended to get updated shots this fall.
• Watch for the next commissioner’s priorities. The next leader will signal whether the agency returns to more traditional scientific processes or continues with the controversial changes Makary introduced.

Expert Perspectives on FDA Leadership

Public health experts generally agree that stable, science-based leadership is essential for the FDA to function properly. Dr. Joshua Sharfstein, a former FDA deputy commissioner now at Johns Hopkins University, has written that frequent leadership changes undermine the agency’s ability to build expertise and maintain consistent standards.

Consumer advocacy groups have also expressed concern. The nonprofit group Public Citizen issued a statement calling for the next commissioner to prioritize patient safety over political pressure. “The FDA must return to its core mission of protecting public health,” the group said.

Industry groups, meanwhile, hope for a leader who can provide clear and predictable guidance. Biotech and pharmaceutical companies need to know what standards their products will be judged against.

Practical Takeaways for Readers

While you cannot control who runs the FDA, you can stay informed and protect your health:

• Keep up with vaccine recommendations from your doctor and the CDC, not just from news about FDA leadership changes
• Check the FDA website for updates on food recalls and drug safety alerts
• Talk to your pharmacist or doctor if you have questions about whether a medication is still considered safe and effective
• Be cautious about health claims that emerge during periods of agency transition, as misinformation can spread when official guidance is unclear

The FDA employs thousands of scientists and inspectors who do critical work every day, regardless of who sits in the commissioner’s office. While leadership changes can create short-term uncertainty, the agency’s career staff continue their work reviewing drugs, inspecting factories, and monitoring food safety.

For now, all eyes are on Washington to see who will be nominated to lead the FDA next. That person will face the same pressures Makary did: balancing industry demands, political interests, and the public’s need for safe and effective medical products. How they handle that balance will shape the health of every American.

Source: MedPage Today